PDSB Logo

PDS Biotechnology Corporation (PDSB) 

NASDAQ
Market Cap
$62.66M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
828 of 960
Rank in Industry
461 of 550

Largest Insider Buys in Sector

PDSB Stock Price History Chart

PDSB Stock Performance

About PDS Biotechnology Corporation

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for …

Insider Activity of PDS Biotechnology Corporation

Over the last 12 months, insiders at PDS Biotechnology Corporation have bought $0 and sold $0 worth of PDS Biotechnology Corporation stock.

On average, over the past 5 years, insiders at PDS Biotechnology Corporation have bought $476,626 and sold $0 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 3,100 shares for transaction amount of $27,860 was made by HILL MATTHEW C () on 2021‑12‑13.

List of Insider Buy and Sell Transactions, PDS Biotechnology Corporation

2021-12-13Purchase
3,100
0.012%
$8.99$27,860-41.56%
2021-06-16Purchase
10,000
0.0456%
$9.88$98,778-4.17%
2021-06-15Purchase
5,882
0.0235%
$8.50$49,997-2.50%
2021-06-15Purchase
5,882
0.0235%
$8.50$49,997-2.50%
2021-06-15Purchase
17,647
0.0704%
$8.50$150,000-2.50%
2021-06-15Purchase
11,764
0.0469%
$8.50$99,994-2.50%
2018-03-22SaleChief Scientific Officer
5,000
0.0161%
$16.41$82,050-94.86%
2018-03-21SaleChief Scientific Officer
5,000
0.0159%
$16.52$82,600-94.94%
2018-03-20SaleChief Scientific Officer
10,000
0.0322%
$16.47$164,700-94.85%
2018-03-19SaleChief Scientific Officer
5,000
0.0161%
$16.59$82,950-94.88%
2018-03-02SalePresident and CEO
5,000
0.0159%
$15.08$75,400-94.24%
2018-03-01SalePresident and CEO
5,000
0.0161%
$14.95$74,725-94.13%
2018-02-23SalePresident and CEO
5,000
0.0158%
$15.37$76,850-94.34%
2018-02-22SaleChief Scientific Officer
5,000
0.0151%
$14.49$72,450-94.25%
2018-02-22SalePresident and CEO
5,000
0.0161%
$15.42$77,100-94.25%
2018-02-21SaleChief Scientific Officer
10,000
0.0304%
$13.82$138,200-93.91%
2018-02-20SaleChief Scientific Officer
10,000
0.0323%
$13.79$137,850-93.48%
2018-02-02SalePresident and CEO
5,000
0.0163%
$12.96$64,800-92.76%
2018-02-01SalePresident and CEO
5,000
0.0159%
$13.05$65,250-92.97%
2018-01-03SalePresident and CEO
5,000
0.0162%
$10.11$50,550-90.32%

Insider Historical Profitability

<0.0001%
HEALY JAMESdirector
2852711
7.6257%
$1.6820<0.0001%
Hove Anders Ddirector
2021917
5.4049%
$1.6810<0.0001%
BARER SOL Jdirector
632810
1.6916%
$1.6810<0.0001%
Bloomquist DeLyle W
193888
0.5183%
$1.6810<0.0001%
Einhorn Andrew J.Chief Financial Officer
81941
0.219%
$1.6810<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
BlackRock$7.4M5.091.87M-0.74%-$55,483.56<0.0001
The Vanguard Group$6.29M4.331.59M+5.46%+$325,254.56<0.0001
Geode Capital Management$2.59M1.78654,185+3.31%+$83,094.84<0.0001
State Street$2.21M1.52557,320+0.96%+$20,940.48<0.0001
Inspirion Wealth Advisors LLC$1.41M0.97354,977+5.46%+$72,796.680.25
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.